Press releases

These press releases are intended for business journalists and analysts/investors

Arzerra® (ofatumumab) registered in Australia for first-line use in chronic lymphocytic leukaemia (CLL)

Arzerra® (ofatumumab) registered in Australia for first-line use in combination with chlorambucil or bendamustine, for the treatment of patients with chronic lymphocytic leukaemia (CLL) who have not received prior therapy and are inappropriate for fludarabine-based therapy.

Read more - Arzerra® (ofatumumab) registered in Australia for first-line use in chronic lymphocytic leukaemia (CLL) Read more

Kimbra launches campaign to urge effective asthma management

Asthma Awareness Week – Popular recording artist and asthma sufferer Kimbra is joining forces with asthma experts and peak respiratory health groups today to launch the Asthma: Take Control campaign. The national campaign is urging people affected by asthma to commit to following the advice given by their healthcare professional to optimise health outcomes.

Read more - Kimbra launches campaign to urge effective asthma management Read more